Tuesday | Wednesday | Thursday | Friday
THURSDAY, DECEMBER 9, 2021
All times are CENTRAL Time    
     
7:00 am - 8:30 am CT POSTER SESSION 3 - Hall 1  
7:00 am - 8:30 am CT SPOTLIGHT POSTER DISCUSSION SESSIONS
 
  Spotlight Poster Discussion 7 - Locoregional Treatment: De-Escalation in Breast Cancer - Stars at Night Ballroom 1&2
 
 

Chair: Wendy A. Woodward
UT MD Anderson Cancer Center
Houston, TX

Reducing and omitting radiotherapy for select breast cancers
Julie A. Bradley, MD, PhD
UF Health Proton Therapy Institute
Jacksonville, FL

Topics in surgical omission: Is less always more? 
Alastair M. Thompson, BSc (Hons), MBChB, MD, FRCS (Ed)
Baylor College of Medicine
Houston, TX

 
  Spotlight Poster Discussion 8 - HER2 Positive Breast Cancer - Stars at Night Ballroom 3&4
 
 

Chair: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Optimizing use of HER2 therapies in metastatic HER2+ breast cancer and other subtypes
Priyanka Sharma, MD
University of Kansas Cancer Center
Westwood, KS

HER2 kinase inhibitors: neoadjuvant approaches and mechanisms of resistance
Cristina Saura Manich, MD
Vall d'Hebron University Hospital
Barcelona, Spain

Novel therapies for HER2+ advanced breast cancer
Jo Chien, MD
University California San Francisco
San Francisco, CA

 
  Spotlight Poster Discussion 9 - Evaluating Emerging and Established Biomarkers - Hall 4A  
 

Co-Chair: W. Fraser Symmans, MB ChB
UT MD Anderson Cancer Center
Houston, TX

Co-Chair: Dennis Sgroi, MD
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

 
8:45 am - 11:15 am CT  GENERAL SESSION 3 - Hall 3

Co-Moderator: Powel Brown, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
and
Co-Moderator: Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
 
8:45 am  GS3-01.  Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
Hurvitz S, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, Kim M-H, Tseng L-M, Petry V, Chung C-F, Iwata H, Hamilton E, Curigliano G, Xu B, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Cortés J. University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; National Cheng Kung University Hospital, Tainan, TaiwanSeoul National University Hospital, Seoul, Republic of KoreaSamsung Medical Center, Seoul, Republic of KoreaClínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda., Sao Paulo, BrazilSeverance Hospital, Yonsei University, Seoul, Republic of Korea; Taipei Veterans General Hospital, Taipei, Taiwan; Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, Sao Paulo, Brazil; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; Aichi Cancer Center Hospital, Aichi, Japan; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; European Institute of Oncology, IRCCS, University of Milano, Milano, Italy; Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China; Daiichi Sankyo, Inc., Basking Ridge, NJ; AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain.
 
 
 
9:00 am  GS3-02.   Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer
Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, Wang X, Yin Y, Cheng Y, Li W, Zhu X, Chen C, Jianjun Zou J. Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Fudan University Cancer Hospital, Shanghai, ChinaJiangsu Cancer Hospital, Nanjing, China; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaTianjin Medical University Cancer Institute and Hospital, Tianjin, China; Beijing Cancer Hospital, Beijing, China; Harbin Medical University Cancer Hospital, Harbin, China; Liaoning Cancer Hospital & Institute, Shenyang, China; Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China; The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Jilin Cancer Hospital, Changchun, China; The First Bethune Hospital of Jilin University, Changchun, China; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
 
 
 
9:15 am  GS3-03.  Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities
Ferraro E, Smith A, Safonov A, Tallon De Lara P, Bernado' C, Arenas Lahuerta EJ, Arribas J, Solit D, Reis-Filho JS, Rosen N, Norton L, Modi S, Robson ME, Dang CT, Curigliano G, Chandarlapaty SRazavi P. Memorial Sloan Kettering Cancer Center, New York City, NY; Vall D'Hebron Institute of Oncology, Barcelona, SpainUniversity of Milan, European Institute of Oncology, Milan, Italy.
 
 
 
9:30 am  GS3-04.  Discussant
Ciara O'Sullivan, MB, BCh
Mayo Clinic
Rochester, MN
 
 
 
9:45 am  GS3-05.   Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
Bidard F-C, Hardy-Bessard A-C, Bachelot T, Pierga J-Y, Canon J-L, Clatot F, Andre F, De La Motte Rouge T, Pistilli B, Dalenc F, Dohollou N, Arsene O, Petit T, Riedl C, Morvan F, Marti A, Lachaier E, Achille M, Gozy M, Escande A, Mille D, Trouboul F, Arnould L, Bieche I, Pradines A, Lemonnier J, Berger F, Delaloge S. Institut Curie, Paris, FranceCARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologie, Plérin, FranceCentre Léon Bérard, Lyon, FranceGrand Hopital de Charleroi, Charleroi, BelgiumCentre Henri Becquerel, Rouen, FranceGustave Roussy, Villejuif, France; Centre Eugène Marquis, Rennes, France; Institut Claudius Régaud, Toulouse, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Centre Hospitalier de Blois, Blois, France; Centre Paul Strauss, Strasbourg, France; Centre Hospitalier Mont de Marsan, Mont de Marsan, France; Centre Hospitalier René Dubos, Cergy-Pontoise, France; Centre Hospitalier d'Auxerre, Auxerre, France; CHU d'Amiens, Amiens, France; Clinique de l'Orangerie, Strasbourg, France; Clinique de l'Europe, Amiens, France; Clinique Sainte Anne, Strasbourg, France; Medipole de Savoie, Challes les eaux, France; Centre Hospitalier Bretagne Atlantique, Vannes, France; Centre Georges François Leclerc, Dijon, France; Unicancer, Paris, France.
 
 
 
10:00 am  GS3-06.  Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer
Turner N, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson I, Okines A, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley A,  Wheatley D, Waters S, Winter M, Bliss J. The Institute of Cancer Research, London, United KingdomThe Institute of Cancer Research & The Royal Marsden Hospital, London, United KingdomClinical Trials and Statistics Unit at The Institute of Cancer Research, London, United KingdomThe Royal Marsden NHS Foundation Trust, London, United KingdomUniversity of Edinburgh, Edinburgh, United KingdomMaidstone Hospital; Maidstone and Tunbridge Wells NHS Trust, Maidstone, United KingdomRoyal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United KingdomThe Beatson West of Scotland Cancer Centre, Glasgow, United KingdomClatterbridge Cancer Centre NHS Trust, Liverpool, United KingdomIndependent Cancer Patients' Voice, London, United KingdomOutreach Research & Innovation Group Ltd and AstraZeneca, Manchester, United KingdomRoyal Cornwall Hospital, Truro, United KingdomVelindre Cancer Centre; Velindre University NHS Trust, Cardiff, United KingdomWeston Park Hospital; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
 
 
 
10:15 am  GS3-07.  Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
Bianchini G, Malorni L, Arpino G, Zambelli A, Puglisi F, Del Mastro L, Colleoni M, Montemurro F, Bianchi G, Paris I, Allegrini G, Cazzaniga ME, Orditura M, Zamagni C, Tamberi S, Castelletti D, Benelli M, Callari M, Santoro A, De Laurentiis M. Department of Oncology, Ospedale San Raffaele, Milano, ItalyDepartment of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Prato, ItalyDepartment of Medical Clinics and Surgery, Università Federico II, Napoli, Italy; U.S.C. Oncologia, Presidio Ospedaliero Papa Giovanni XXIII, Bergamo, Italy; S.O.C. Oncologia Medica e Prevenzione Oncologica, IRCCS, Centro di Riferimento Oncologico, Aviano, ItalyU.O.S.D. Breast Unit, I.R.C.C.S. Ospedale Policlinico San Martino, Genoa, Italy; Senologia Medica, IEO, Istituto Europeo di Oncologia, IRCCS,, Milano, ItalyIstituto di Candiolo, FPO, IRCCS, Candiolo,, Torino, Italy; SC Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; Department of Woman and Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyU.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy; Phase 1 Research Unit & Oncology Unit, Azienda Socio Sanitaria Territoriale Monza & Milano Bicocca School of Medicine and Surgery, Monza, Italy; U.O.C. Oncologia Medica e Ematologia, A.O.U. Università Degli Studi L. Vanvitelli, Napoli, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; U.O. Oncologia, P.O. Ospedale degli Infermi – AUSL, Ravenna, Italy; Oncology, Novartis Farma SpA, Origgio, Italy; Department of Oncology and Bioinformatics Unit, Ospedale di Prato, Azienda USL Toscana Centro, Prato, Italy; CRUK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, United Kingdom; IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy.
 
 
 
10:30 am  GS3-08.  Discussant
Minetta C. Liu, MD
Mayo Clinic
Rochester, MN
 
 
 
10:45 am  GS3-09.  Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer
Sudhan DR, Chatterjee S, Kim J, Wang Y, Kandagatla V, Ye D, Lin C-C, Gomez Tejeda Zanudo J, Jain E, Marin A, Servetto A, Lee K-m, Povedano JM, McFadden D, Barrett A, Wagle N, Hanker AB, Arteaga CL. UT Southwestern Medical Center, Dallas, TX; Dana Farber Cancer Institute, Boston, MA; TEMPUS, Chicago, IL.
 
     
11:00 am  GS3-10.  Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Coombes C, Howell SJ, Krebs MG, Lord S, Kenny LM, Bahl A, Clack G, Ainscow E, Dickinson PA, Fostea R, Mansi J, Palmieri C, Bertelli G, Jeselsohn R, Mitri Z, Gradishar WJ, Sardesai S, O'Shaughnessy J, Ward P, Chalasani P, Lehnert M, Ali S, McIntosh S. Imperial College, London, United Kingdom; The University of Manchester, Manchester, United Kingdom; The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Carrick Therapeutics, Dublin, Ireland; SEDA Pharmaceutical Development Services, Stockport, United Kingdom; HCA Healthcare, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom; Brighton and Sussex University Hospital, Brighton, United Kingdom; Dana Faber Cancer Institute, Boston, MA; Oregon Health & Science University, Portland, OR; North Western University, Chicago, IL; The Ohio State University, Columbus, OH; The US Oncology Network, Dallas, TX; The University of Arizona, Tucson, AZ.
 
 
 
11:15 am Break  
     
10:00 am - 5:00 pm CT EXHIBITS - Hall 2  
11:30 am - 12:30 pm CT DEBATE - Hall 3  
 

RxPONDER: Was it all OFS?
Chair: Harold Burstein MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Pro
Michael Gnant, MD
Medical University of Vienna
Vienna, Austria

Con
Sibylle Loibl, Dr Med
GBG Forschungs GmbH
Hessen, Germany

 

 
12:30 pm - 1:00 pm CT AACR Distinguished Lectureship in Breast Cancer Research, supported by Aflac Inc. - Hall 3
Translation of fundamental cell cycle principles to targeted cancer therapies
Helen M. Piwnica-Worms, PhD
University of Texas MD Anderson Cancer Center
Houston, TX
 
1:30 pm - 2:00 pm CT  PLENARY LECTURE 1 - Hall 3  

Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine
Mitchell Dowsett, PhD
Royal Marsden Hospital
London, United Kingdom
 
2:00 pm - 3:00 pm CT TRANSLATIONAL SCIENCE FORUM  
 

HER2 Heterogeneity - Hall 4A
Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Baylor College of Medicine
Houston, TX

A journey through the life of HER2: How did we get here and where are where are we going?
Kim RM Blenman, PhD, MS
Yale Cancer Center
Yale University
New Haven, CT

Heterogeneity in treatment outcomes for HER2+ breast cancer – Clinical management strategies
Sara M. Tolaney, MD, MPH
Dana Farber Cancer Institute
Boston, MA

Molecular heterogeneity in HER2+ breast cancer – can outcomes be predicted?
Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

 
  CLINICAL SCIENCE FORUM  
 

The Promise and Reality of Oligometastatic Ablation for Breast Cancer - Stars at Night Ballroom 3&4
Moderator: Steven J. Chmura, MD, PhD
University of Chicago
Chicago, IL

Oligometastatic disease: Definitions and practice patterns
Yolande Lievens, MD, PhD
Ghent University Hospital
Ghent, Belgium

Current evidence for ablative therapies for oligometastatic disease
David Palma, MD, PhD
London Health Sciences Centre
Ontario, Canada

 

MOLECULAR TUMOR BOARD - Stars at Night Ballroom 1&2
Moderator: Ben Ho Park, MD, PhD
Vanderbilt University Medical Center
Nashville, TN

Panel Members:

Fabrice Andre
Mark E. Burkard
Sarat Chandarlapaty
Susan Domchek
Diana Mandelker
Bob Riter
Aditya Bardia     

 
3:00 pm - 5:00 pm CT EDUCATIONAL SESSIONS  
 

Local Therapy of the Primary and Beyond in Patients with Advanced Disease - Hall 4A
Moderators: Rajendra A. Badwe, MBBS, MS
Tata Memorial Centre
Mumbai, India

and

Seema Khan, MD
Northwestern University
Chicago, IL

Local therapy of the primary tumor
Seema Khan, MD
Northwestern University
Chicago, IL

Special indications where local therapy should be considered
Anthony Lucci, MD
UT MD Anderson Cancer Center
Houston, TX

Oligo-progressive disease. Treating locally more than systemically
Amy Xu, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Clinical Updates on Immunotherapy - Hall 3
Moderator: Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom

Immunotherapy in the metastatic setting - chemo backbone and biomarker
Rebecca Dent, MD
National Cancer Center
Singapore

Immune therapy in the (neo) adjuvant setting
Heather L. McArthur, MD, MPH
UT Southwestern
Dallas, TX

IO beyond TNBC
Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milan, Italy

 

Anti-cancer Immune Response - Hall 4B
Moderator: Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Immune responses against Breast Cancer: Concepts and Future Developments
Laurence Zitvogel, MD, PhD
Institut Gustave Roussy
Villejuif, France

Macro and micro: Macrophage and microbiome diversity in the breast cancer microenvironment
Jennifer L. Guerriero, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Optimizing immunotherapy efficacy in the clinic through biomarkers: Advances in single cell and spatial histology analyse
Marleen Kok, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherland

 

The Fluid Landscape of Liquid Biopsy - Stars at Night Ballroom 3&4
Moderator: Nicholas Turner, PhD, FRCF
The Royal Marsden Hospital Institute of Cancer Research
London, United Kingdom

and

Moderator: Massimo Cristofanilli, MD, FRCF
Northwestern University
Chicago, IL

Monitoring of advanced breast cancer with liquid biopsies
François-Clément Bidard, MD, PhD
Institut Curie
Paris Saclay University
Paris, France

Single cell analysis of circulating tumor cells
Shyamala Maheswaran, PhD
Massachusetts General Hospital
Boston, MA

Challenges in early detection - screening and MRD
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

 

Targeting the "Un-druggable" - Stars at Night Ballroom 1&2
Moderator: Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
Houston, TX

Targeting EZH2 functions
Celina G. Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

RNA metabolism and splicing
Trey Westbrook, PhD
Baylor College of Medicine
Houston, TX

Novel epigenomic targets in TNBC
David W. Cescon, MD, PhD
Princess Margaret Cancer Centre
Toronto, Canada

 
     
 5:00 pm - 6:30 pm CT POSTER SESSION 4 - Hall 1  
  SPOTLIGHT POSTER DISCUSSION SESSIONS  
  Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches - Stars at Night Ballroom 1&2
 
 

Chair: Kevin Kalinsky, MD, MS
Winship Cancer Institute
Emory University
Atlanta, GA

Rebecca A. Shatsky, MD
UC San Diego Health
San Diego, CA

David B. Page, MD
Providence Cancer Institute
Portland, OR

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
 

 
  Spotlight Poster Discussion 11 - The Future is Now: Innovation in Pathology and Radiology - Stars at Night Ballroom 3&4  
 

Co-Chair: Kalliopi P. Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Co-Chair: Sughra Raza, MD
University of Massachusetts Medical School
Worcester, MA

Innovation in Pathology
Lee A. Cooper, PhD
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL

Innovation in Radiology
Linda Moy, MD
NYU Langone
New York, NY

 
 


 
7:00 pm - 8:45 pm CT OPEN SATELLITE EVENT In-person Symposium will be held at the San Antonio Marriott Rivercenter hotel.  
  What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Triple-Negative Breast Cancer (Part 3 of a 3-Part CME Series (Part 3 of a 3-Part CME Series) presented by Research To Practice  
  Register for this complimentary in-person symposia or virtual event: http://www.researchtopractice.com/Meetings/SA2021
 
     
7:00 pm - 9:00 pm CST OPEN SATELLITE EVENT In-person Symposium will be held at the San Antonio Marriott Rivercenter hotel.  
  Candid Conversations & Clinical Consults: Personalizing Treatment Decisions in HER2-Altered Breast Cancer - Strategies for Improving Equity and Patient Outcomes Through Individualized Targeted Therapy Selection, Team-Based Care, and Shared Decision-Making presented by PVI, PeerView Institute for Medical Education  
  Register for this this complimentary live symposia or virtual event
In-Person Symposium: PeerView.com/SanAntonio21-Live
Live Web Broadcast: PeerView.com/SanAntonio2021-Virtual
 
 
Tuesday | Wednesday | Thursday | Friday